AChRα(97-116)
Based on 1 Customer Validation
AChRα(97-116) is a synthetic peptide corresponding to the 97-116 region of the rat acetylcholine receptor α-subunit, and also an inducer of autoimmune diseases. AChRα(97-116) can be used in studies related to experimental autoimmune myasthenia gravis.
For research use only. We do not sell to patients.
- Purity: 95.34%
- CAS No.: 663154-30-1
- Formula: C106H162N24O30
- Molecular Weight:2252.56
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
AChRα(97-116) (10 μg/mL; 72 h) does not induce significant proliferation of lymphocytes harvested from MBP68-86-immunized Lewis rats[1].
AChRα(97-116) (10 μg/mL; 48 h) maintains the antigen-specific immune cell phenotype responsive to dopaminergic modulation in recall-stimulated EAMG rat-derived CD4+ T cells and B220+ B cells[2].
AChRα(97-116) (2 μg/mL; overnight at 4 °C) effectively detects elevated AChR-specific antibody levels in EAMG rat serum and dopamine-stimulated EAMG rat splenocyte supernatants[2].
AChRα(97-116) (10 μg/mL; 24 h pre-incubation + 24 h co-culture) stimulates CD4+ T cells from EAMG rats to differentiate into AChR-specific Tfh cells at a 3-4-fold higher ratio than in control rats, and these Tfh cells promote increased IgG2b-secreting B cell percentages and anti-AChR antibody production in co-cultures with EAMG-derived B cells[3].
AChRα(97-116) (10 μg/mL; 72 h) stimulates lymph node-derived mononuclear cells from EAMG rats to produce elevated percentages of CD4+CXCR5+ and CD4+ICOS+ pre-Tfh cells following 72 h of incubation[3].
AChRα(97-116) (2 μg/mL; overnight at 4°C) coated on ELISA plates enables detection of significantly elevated anti-AChR antibody levels in serum from EAMG rats across multiple time points and dilutions compared to control rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Immunization with AChRα(97-116) (50 μg; subcutaneous injection; day 0 and day 30) induces experimental autoimmune myasthenia gravis in Lewis rats with >85% efficiency, driving elevated anti-AChR antibody production, reduced muscle AChR clusters, and expansion of AChR-specific pre-Tfh and mature Tfh cells that promote germinal center formation and B cell antibody secretion[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Lewis rats (female, 6-8 weeks old, 140-160 g, immunization-induced experimental autoimmune myasthenia gravis)[2]
-
Dosage:50 μg/rat
-
Administration:tail root injection; two doses (first with Mycobacterium tuberculosis-containing emulsion, second on day 30 without Mycobacterium tuberculosis)
-
Result:Induced a significant increase in clinical scores from day 40 onward.
Caused a significant decline in body weight starting on day 42 after the second immunization.
Reduced α-bungarotoxin fluorescence intensity and caused intermittent morphology at neuromuscular junctions.
Elevated serum AChR-specific antibody levels significantly.
Chemical Information
-
CAS No. 663154-30-1
-
Appearance Solid
-
Molecular Weight 2252.56
-
Formula C106H162N24O30
-
Color White to off-white
-
Sequence
Asp-Gly-Asp-Phe-Ala-Ile-Val-Lys-Phe-Thr-Lys-Val-Leu-Leu-Asp-Tyr-Thr-Gly-His-Ile
-
Sequence Shortening
DGDFAIVKFTKVLLDYTGHI
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
0.5 M NaOH : 100 mg/mL (44.39 mM; Need ultrasonic)
DMSO : 28.57 mg/mL (12.68 mM; ultrasonic and adjust pH to 2 with 1 M HCl; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.22 mg/mL (0.99 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.22 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (22.2 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Liu YM,et al. The effect of electroacupuncture on T cell responses in rats with experimental autoimmune encephalitis. J Neuroimmunol. 2010 Mar 30;220(1-2):25-33. [Content Brief]
[2]. Hao Y, et al. Impaired cerebral microvascular endothelial cells integrity due to elevated dopamine in myasthenic model. J Neuroinflammation. 2024;21(1):10. Published 2024 Jan 4. [Content Brief]
[3]. Cui YZ, et al. Enhancement of T Follicular Helper Cell-Mediated Humoral Immunity Reponses During Development of Experimental Autoimmune Myasthenia Gravis. Neurosci Bull. 2019;35(3):507-518. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / 0.5 M NaOH | 1 mM | 0.4439 mL | 2.2197 mL | 4.4394 mL | 11.0985 mL |
| 5 mM | 0.0888 mL | 0.4439 mL | 0.8879 mL | 2.2197 mL | |
| 10 mM | 0.0444 mL | 0.2220 mL | 0.4439 mL | 1.1098 mL | |
| 0.5 M NaOH | 15 mM | 0.0296 mL | 0.1480 mL | 0.2960 mL | 0.7399 mL |
| 20 mM | 0.0222 mL | 0.1110 mL | 0.2220 mL | 0.5549 mL | |
| 25 mM | 0.0178 mL | 0.0888 mL | 0.1776 mL | 0.4439 mL | |
| 30 mM | 0.0148 mL | 0.0740 mL | 0.1480 mL | 0.3699 mL | |
| 40 mM | 0.0111 mL | 0.0555 mL | 0.1110 mL | 0.2775 mL |
Powered by Bioz